257 related articles for article (PubMed ID: 20071590)
21. Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors.
Elhefnawi M; ElGamacy M; Fares M
BMC Bioinformatics; 2012; 13 Suppl 17(Suppl 17):S5. PubMed ID: 23282180
[TBL] [Abstract][Full Text] [Related]
22. Interference of HCV replication by cell penetrable human monoclonal scFv specific to NS5B polymerase.
Thueng-in K; Thanongsaksrikul J; Jittavisutthikul S; Seesuay W; Chulanetra M; Sakolvaree Y; Srimanote P; Chaicumpa W
MAbs; 2014; 6(5):1327-39. PubMed ID: 25517317
[TBL] [Abstract][Full Text] [Related]
23. Structural basis for resistance of the genotype 2b hepatitis C virus NS5B polymerase to site A non-nucleoside inhibitors.
Rydberg EH; Cellucci A; Bartholomew L; Mattu M; Barbato G; Ludmerer SW; Graham DJ; Altamura S; Paonessa G; De Francesco R; Migliaccio G; Carfí A
J Mol Biol; 2009 Jul; 390(5):1048-59. PubMed ID: 19505479
[TBL] [Abstract][Full Text] [Related]
24. In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
Shi ST; Herlihy KJ; Graham JP; Fuhrman SA; Doan C; Parge H; Hickey M; Gao J; Yu X; Chau F; Gonzalez J; Li H; Lewis C; Patick AK; Duggal R
Antimicrob Agents Chemother; 2008 Feb; 52(2):675-83. PubMed ID: 18070954
[TBL] [Abstract][Full Text] [Related]
25. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
Ali S; Leveque V; Le Pogam S; Ma H; Philipp F; Inocencio N; Smith M; Alker A; Kang H; Najera I; Klumpp K; Symons J; Cammack N; Jiang WR
Antimicrob Agents Chemother; 2008 Dec; 52(12):4356-69. PubMed ID: 18838588
[TBL] [Abstract][Full Text] [Related]
26. Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition.
Biswal BK; Wang M; Cherney MM; Chan L; Yannopoulos CG; Bilimoria D; Bedard J; James MN
J Mol Biol; 2006 Aug; 361(1):33-45. PubMed ID: 16828488
[TBL] [Abstract][Full Text] [Related]
27. Recent advances in discovery and development of promising therapeutics against hepatitis C virus NS5B RNA-dependent RNA polymerase.
Wu JZ; Yao N; Walker M; Hong Z
Mini Rev Med Chem; 2005 Dec; 5(12):1103-12. PubMed ID: 16375756
[TBL] [Abstract][Full Text] [Related]
28. Nucleoside analog inhibitors of hepatitis C virus replication.
Carroll SS; Olsen DB
Infect Disord Drug Targets; 2006 Mar; 6(1):17-29. PubMed ID: 16787301
[TBL] [Abstract][Full Text] [Related]
29. PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
Lam AM; Murakami E; Espiritu C; Steuer HM; Niu C; Keilman M; Bao H; Zennou V; Bourne N; Julander JG; Morrey JD; Smee DF; Frick DN; Heck JA; Wang P; Nagarathnam D; Ross BS; Sofia MJ; Otto MJ; Furman PA
Antimicrob Agents Chemother; 2010 Aug; 54(8):3187-96. PubMed ID: 20516278
[TBL] [Abstract][Full Text] [Related]
30. Inhibitors of hepatitis C virus polymerase: synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides.
Cheng CC; Shipps GW; Yang Z; Kawahata N; Lesburg CA; Duca JS; Bandouveres J; Bracken JD; Jiang CK; Agrawal S; Ferrari E; Huang HC
Bioorg Med Chem Lett; 2010 Apr; 20(7):2119-24. PubMed ID: 20219368
[TBL] [Abstract][Full Text] [Related]
31. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.
Howe AY; Cheng H; Johann S; Mullen S; Chunduru SK; Young DC; Bard J; Chopra R; Krishnamurthy G; Mansour T; O'Connell J
Antimicrob Agents Chemother; 2008 Sep; 52(9):3327-38. PubMed ID: 18559648
[TBL] [Abstract][Full Text] [Related]
32. Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders.
Eltahla AA; Tay E; Douglas MW; White PA
Antimicrob Agents Chemother; 2014 Dec; 58(12):7215-24. PubMed ID: 25246395
[TBL] [Abstract][Full Text] [Related]
33. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.
Kukolj G; McGibbon GA; McKercher G; Marquis M; Lefèbvre S; Thauvette L; Gauthier J; Goulet S; Poupart MA; Beaulieu PL
J Biol Chem; 2005 Nov; 280(47):39260-7. PubMed ID: 16188890
[TBL] [Abstract][Full Text] [Related]
34. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus.
Le Pogam S; Kang H; Harris SF; Leveque V; Giannetti AM; Ali S; Jiang WR; Rajyaguru S; Tavares G; Oshiro C; Hendricks T; Klumpp K; Symons J; Browner MF; Cammack N; Nájera I
J Virol; 2006 Jun; 80(12):6146-54. PubMed ID: 16731953
[TBL] [Abstract][Full Text] [Related]
35. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
Ahmed-Belkacem A; Ahnou N; Barbotte L; Wychowski C; Pallier C; Brillet R; Pohl RT; Pawlotsky JM
Gastroenterology; 2010 Mar; 138(3):1112-22. PubMed ID: 19962982
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons.
Belema M; Nguyen VN; Romine JL; St Laurent DR; Lopez OD; Goodrich JT; Nower PT; O'Boyle DR; Lemm JA; Fridell RA; Gao M; Fang H; Krause RG; Wang YK; Oliver AJ; Good AC; Knipe JO; Meanwell NA; Snyder LB
J Med Chem; 2014 Mar; 57(5):1995-2012. PubMed ID: 24437689
[TBL] [Abstract][Full Text] [Related]
37. Mapping cooperative activity of the hepatitis C virus RNA-dependent RNA polymerase using genotype 1a-1b chimeras.
Gu B; Gutshall LL; Maley D; Pruss CM; Nguyen TT; Silverman CL; Lin-Goerke J; Khandekar S; Liu C; Baker AE; Casper DJ; Sarisky RT
Biochem Biophys Res Commun; 2004 Jan; 313(2):343-50. PubMed ID: 14684166
[TBL] [Abstract][Full Text] [Related]
38. Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection.
Sims KD; Lemm J; Eley T; Liu M; Berglind A; Sherman D; Lawitz E; Vutikullird AB; Tebas P; Gao M; Pasquinelli C; Grasela DM
Antimicrob Agents Chemother; 2014 Jun; 58(6):3496-503. PubMed ID: 24733462
[TBL] [Abstract][Full Text] [Related]
39. Current perspective of HCV NS5B inhibitors: a review.
Patil VM; Gupta SP; Samanta S; Masand N
Curr Med Chem; 2011; 18(36):5564-97. PubMed ID: 22172066
[TBL] [Abstract][Full Text] [Related]
40. Thumb inhibitor binding eliminates functionally important dynamics in the hepatitis C virus RNA polymerase.
Davis BC; Thorpe IF
Proteins; 2013 Jan; 81(1):40-52. PubMed ID: 22855387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
